Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;12(1):2-6.
doi: 10.1093/neuonc/nop002. Epub 2009 Oct 15.

Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas

Caroline Houillier  1 , Karima Mokhtari, Catherine Carpentier, Emmanuelle Crinière, Yannick Marie, Audrey Rousseau, Gentian Kaloshi, Caroline Dehais, Julien Laffaire, Florence Laigle-Donadey, Khê Hoang-Xuan, Marc Sanson, Jean-Yves Delattre
Affiliations

Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas

Caroline Houillier et al. Neuro Oncol. 2010 Jan.

Abstract

The loss of chromosomes 1p-19q is the only prognostic molecular alteration identified in low-grade gliomas (LGGs) to date. Search for loss of heterozygosity (LOH) on chromosomes 1p, 9p, 10q, and 19q was performed in a series of 231 LGGs. Loss of chromosomes 1p-19q was strongly correlated with prolonged progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analyses. LOH on 9p and 10q were associated with shortened PFS (P = .01 and .03, respectively) on univariate analysis. On multivariate analysis, LOH on 9p remained significant for PFS (P = .05), whereas LOH on 10q had a significant effect on OS (P = .02). Search for LOH 9p and 10q appears to be a useful complement to analysis of chromosomes 1p-19q in LGGs.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
The prognostic advantage conferred by deletion of chromosomes 1p–19q on PFS is lost in patients with combined chromosome 9p loss.
See this image and copyright information in PMC

References

    1. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma. European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–556. - PubMed
    1. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–2084. - PubMed
    1. Shaw E, Arusell R, Scheuthauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–2276. - PubMed
    1. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer. 2006;106:1358–1363. - PubMed
    1. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831–1836. - PubMed

Publication types